Cargando…
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse eve...
Autores principales: | Cheng, Ke, Wang, Yuqing, Zhou, Yuwen, Xia, Ruolan, Tang, Liansha, Liu, Jiyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637700/ https://www.ncbi.nlm.nih.gov/pubmed/34866959 http://dx.doi.org/10.1177/11795549211056261 |
Ejemplares similares
-
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
por: Tang, Liansha, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021) -
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
por: Guidon, Amanda C, et al.
Publicado: (2021) -
Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy
por: Möhn, Nora, et al.
Publicado: (2020) -
Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments
por: Xia, Ruolan, et al.
Publicado: (2021)